BIZARRE: Is amgen stock underperforming the dow - You Need To See This

Amgen Inc. (AMGN), incorporated in 1980 and headquartered in Thousand Oaks, California, is a biotech titan that crafts life-saving therapies that combat everything from cancer and osteoporosis to autoimmune disorders. Known for breakthroughs like Enbrel, Prolia, and Repatha, it blends cutting-edge science with strategic alliances to tackle humanity's toughest health challenges. Amgen, boasting a market cap of over $152 billion, serves patients worldwide.

Companies worth $10 billion or more are described as “large-cap stocks,” and Amgen fits this category. Anchored by blockbuster drugs like Enbrel and Aranesp, the biopharma giant, with strong financials and a forward-thinking approach, stands tall in a competitive industry - proving it’s not just big by name but by its relentless drive to innovate and dominate.